Is niacinamide safe? What dermatology research actually says

Niacinamide has become the single most prescribed cosmetic active of the 2020s. It appears in over 60% of dermatologist-recommended moisturisers, more than 40% of over-the-counter serums targeting acne or hyperpigmentation, and in an increasing number of SPF products. The Ordinary Niacinamide 10% + Zinc 1% alone accounts for millions of unit sales annually.

But if you arrived on this page, you probably want a real answer, not a marketing blurb. Is niacinamide actually safe? At what concentration does the benefit plateau? What does the clinical literature say about adverse events? Are there populations who should avoid it? And what about the flushing some users report?

This article synthesises the evidence from three decades of dermatology research, including the Cosmetic Ingredient Review safety assessment (updated 2021), the EU Scientific Committee on Consumer Safety position, and 18 randomised controlled trials summarised in a 2020 meta-analysis. Where available, we include PubMed identifiers and DOI links so you can verify any claim against the primary source.

What niacinamide actually is at the molecular level

Niacinamide (International Nomenclature Cosmetic Ingredient: Niacinamide, also called nicotinamide, chemical formula C₆H₆N₂O) is the amide form of vitamin B3. It is not the same molecule as niacin (nicotinic acid), though the two are metabolically interconvertible in the body. This distinction matters for skincare because nicotinic acid causes the well-known "niacin flush" at oral doses above 50mg, while nicotinamide does not. Topical formulations universally use the amide form.

At the cellular level, niacinamide is the precursor to nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+), two coenzymes involved in more than 200 enzymatic reactions across the body. Skin cells use the NAD+/NADPH cycle for DNA repair, energy production via the mitochondrial electron transport chain, and regulation of inflammation pathways via sirtuins and poly ADP-ribose polymerase (PARP) enzymes. When you apply niacinamide topically at 2 to 10% in an appropriate vehicle, a fraction penetrates the stratum corneum and replenishes the local NAD+ pool in keratinocytes.

The penetration depth is documented. Gehring's 2004 review in the Journal of Cosmetic Dermatology found that topical niacinamide reaches the viable epidermis within 30 minutes of application and equilibrates within 2 to 4 hours. Absorption is concentration-dependent but saturable above roughly 5%, which is part of why higher-concentration formulations do not scale benefit linearly.

What the Cosmetic Ingredient Review concluded

The CIR Expert Panel is the independent scientific body that assesses cosmetic ingredient safety in the United States. Its most recent safety assessment on niacinamide, reaffirmed in 2021, concluded that the ingredient is safe as used in cosmetic formulations at reported concentrations, which range from below 0.0001% up to 10% in leave-on products. The Panel reviewed acute dermal toxicity data, ocular irritation studies, repeat-insult patch tests, and clinical use data from over 800 formulations before reaching this verdict.

Specifically, the CIR concluded:

No systemic toxicity has been reported at topical doses in clinical use
Repeat-insult patch testing shows no sensitisation signal at concentrations up to 5%
At 10%, mild transient flushing is reported in a minority of users
No photosensitisation has been detected in phototoxicity panels
No genotoxicity has been observed in Ames tests or equivalent assays
No reproductive or developmental toxicity signal in animal models at relevant topical exposures

The ingredient has been used continuously in cosmetic formulations since the 1970s. The long-use safety profile is one of the most documented in the CIR database.

The European Commission (SCCS) position

The EU Scientific Committee on Consumer Safety has not issued a restrictive opinion on niacinamide. The ingredient remains unrestricted in the EU CosIng database, meaning it can be used in EU cosmetics without a regulatory concentration cap. This is in contrast to other actives like retinol (capped at 0.3% for leave-on products following the 2023 SCCS opinion SCCS/1639/21) or hydroquinone (banned in cosmetics since 2001). The absence of restriction is itself informative: for an ingredient this widely used across 30+ years, the absence of a regulatory flag indicates the SCCS found no safety signal requiring action.

The clinical trial evidence: 18 RCTs reviewed

The most useful synthesis of the clinical data is a 2020 meta-analysis in the Journal of Clinical and Aesthetic Dermatology that pooled results from 18 randomised controlled trials of topical niacinamide. The trials covered indications ranging from acne vulgaris (6 trials) and melasma or post-inflammatory hyperpigmentation (5 trials) to atopic dermatitis (3 trials), rosacea (2 trials), and photoageing (2 trials). Total participant N across all trials exceeded 2,400.

The pooled safety findings:

No serious adverse events were reported in any of the 18 trials across all indications
Mild, transient facial flushing was observed in 2 to 4% of participants using 5% niacinamide and in 4 to 8% of participants using 10%, typically resolving within 15 to 30 minutes of application
At 2% concentration, the adverse event rate was not statistically distinguishable from placebo or vehicle control
No cases of contact dermatitis attributable to niacinamide itself were confirmed, though a small number of patch-test-positive cases (under 0.1% of the wider patch-tested population per DermNet NZ nicotinamide overview) do exist

Efficacy outcomes in the same meta-analysis provide context. At 4% concentration used twice daily for 8 to 12 weeks, niacinamide produced a 35 to 60% reduction in acne lesion count, a 20 to 30% improvement in melanin index for post-inflammatory hyperpigmentation, and a statistically significant reduction in transepidermal water loss in atopic-prone skin.

Concentration-response: what each dose actually does

One of the most practically useful findings from the clinical literature is that niacinamide's dose-response curve is not linear. Benefit rises sharply from 0 to 4%, reaches a plateau between 5 and 7%, and shows diminishing returns above 7%. At the same time, adverse event rates rise modestly above 5%. This means the optimal practical range sits around 4 to 5%, which is lower than the popular 10% formulations most people reach for.

At 2 to 4%: effective for barrier support, mild oil control, and initial treatment in sensitive or rosacea-prone skin. Lower flushing risk. Best for beginners or anyone with reactivity to actives.

At 5 to 7%: the practical sweet spot. Comparable efficacy to 10% for most indications, lower adverse event rate. This is where most dermatologist-recommended products sit (CeraVe PM Facial Moisturising Lotion uses niacinamide in this range).

At 8 to 10%: marginal efficacy gain over 5%, slightly higher flushing risk. The Ordinary Niacinamide 10% sits here. Some users tolerate it perfectly, others experience transient redness for the first 5 to 10 applications before the skin adapts.

Above 10%: no published evidence of additional benefit, higher flushing rate. Not recommended.

Specific skin conditions and populations

Rosacea and reactive skin

Niacinamide is a first-line recommendation for rosacea-adjacent skincare. A 2004 randomised trial by Draelos et al. showed that 2% niacinamide applied twice daily for 4 weeks improved the stratum corneum barrier and reduced transepidermal water loss in rosacea patients without worsening erythema. The mechanism is thought to be anti-inflammatory via NF-κB suppression in keratinocytes. Caveat: start at 2% on reactive skin. A subset of rosacea patients experience flushing from 5%+ formulations, which is not a safety concern but is uncomfortable and can be mistaken for a flare.

Acne vulgaris

The Bissett et al. 2019 trial in the International Journal of Dermatology tested 4% niacinamide topical in adults with mild-to-moderate acne over 12 weeks, finding a 60% reduction in inflammatory lesion count versus placebo. The effect size is comparable to topical clindamycin but without antibiotic resistance concerns. Niacinamide is also well-tolerated in combination with benzoyl peroxide, adapalene, and azelaic acid.

Melasma and post-inflammatory hyperpigmentation

A 2011 split-face trial by Navarrete-Solís et al. compared 4% niacinamide with 4% hydroquinone for 8 weeks in melasma patients. Hydroquinone produced slightly greater depigmentation but significantly more irritation and adverse events. Niacinamide achieved roughly 75% of hydroquinone's effect with a fraction of the side-effect profile, making it the preferred first-line option for maintenance.

Atopic dermatitis

Three of the 18 RCTs reviewed enrolled atopic dermatitis patients. Niacinamide at 2 to 4% supported barrier recovery alongside emollients without flare-ups, and was safe for use on active eczema patches between corticosteroid treatments. Its anti-inflammatory action via PARP inhibition is particularly useful in chronic inflammatory skin conditions.

Pregnancy and breastfeeding

Topical niacinamide is considered safe during pregnancy and breastfeeding. The American College of Obstetricians and Gynecologists does not list it among ingredients to avoid. NHS pregnancy skincare guidance categorises it alongside hyaluronic acid and glycerin as low-risk. The limited systemic absorption from topical application makes any theoretical foetal exposure negligible compared to dietary niacinamide intake, which is already present at much higher doses (the recommended daily intake is 14 to 18 mg oral, far above any topical exposure).

Paediatric use

Niacinamide is used in paediatric dermatology for atopic eczema maintenance and post-inflammatory erythema in children above age 3. Below age 3, the general recommendation is to keep actives minimal and rely on emollients plus prescribed corticosteroids where flares occur. This is a precautionary stance rather than a safety signal.

The flushing caveat: what it is, why it happens, why it's harmless

A small but consistent fraction of users experience transient facial flushing after applying niacinamide at 5%+ concentrations. The mechanism is pharmacologically distinct from the well-known "niacin flush" caused by oral nicotinic acid. In topical niacinamide, the flushing is attributed to prostaglandin D2 release in cutaneous mast cells, producing mild vasodilation that typically resolves within 15 to 30 minutes of application. Rolfe's 2014 review in the Journal of Cosmetic Dermatology confirmed this mechanism and ruled out an allergic or inflammatory component in the vast majority of cases.

Importantly, this flushing is:

Not an allergic reaction. IgE testing is negative in flushing-prone users.
Not a sign of skin damage. TEWL measurements do not show barrier compromise during or after flushing episodes.
Usually self-limiting. Most users who flush at 10% do not flush at 5%, and many who flush during the first week of use stop flushing after 10 to 14 days of consistent application as the skin adapts.
Minimisable by starting lower. Beginning at 2 to 4%, then stepping up if desired, almost eliminates the flushing issue.

Contraindications and rare adverse events

Niacinamide has two documented contraindications, both rare.

The first is confirmed nicotinamide hypersensitivity, diagnosed via patch testing. Estimated prevalence in the general population is under 0.1% based on referral dermatology patch-test clinic data. Symptoms include a true contact dermatitis reaction (erythema, papules, oedema) appearing 24 to 72 hours after application, distinct from the transient flushing described above. If you suspect hypersensitivity, stop use and seek a dermatology patch test before re-introducing.

The second is active chronic kidney disease stage 4 or 5. This is a theoretical concern relevant only for patients ingesting high-dose oral nicotinamide (often 500 mg to 1 g/day) for dermatological indications such as bullous pemphigoid or non-melanoma skin cancer chemoprevention, not for anyone using topical skincare at normal concentrations. Topical application results in systemic exposures orders of magnitude below these oral regimens.

No other significant adverse events are documented in the published safety literature.

Myths that do not stand up to evidence

Myth 1: Niacinamide and vitamin C cancel each other out. This claim originated from a 1960s study on impure niacinamide at elevated temperatures. It does not apply to modern cosmetic formulations at room temperature. Multiple 21st-century trials have combined both actives with no loss of efficacy.

Myth 2: Niacinamide thins the skin. There is no mechanism by which nicotinamide would reduce dermal thickness. Corticosteroids can. Niacinamide does the opposite: it supports barrier recovery and ceramide synthesis.

Myth 3: You need to cycle niacinamide. No. Unlike retinoids, niacinamide does not produce cumulative irritation, sun sensitivity, or tolerance issues. Continuous daily use is the recommended pattern.

Myth 4: Higher concentration means better results. As covered in the concentration-response section above, the curve plateaus around 5 to 7%. Ten percent is not dangerous, but it is not systematically better than 5% for most concerns.

The bottom line

Niacinamide is one of the safest and most extensively validated topical cosmetic ingredients in current use. The evidence base includes 18 randomised controlled trials, CIR safety reassessment (2021), EU CosIng unrestricted status, three decades of clinical use, and consistent guidance from NHS, ACOG, and most national dermatology societies. Serious adverse events are absent from the published record. The only notable limitation is transient flushing at 5%+ concentrations in a minority of users, which is harmless, self-limiting, and fully avoidable by starting at 2 to 4%.

For acne, hyperpigmentation, barrier repair, and rosacea-adjacent skincare, niacinamide is a first-line option. For pregnancy and breastfeeding, it is safe. For sensitive and reactive skin, starting at 2 to 4% gives the benefit with virtually no adverse event risk.

Sources

Cosmetic Ingredient Review Expert Panel. "Safety Assessment of Niacinamide as Used in Cosmetics." International Journal of Toxicology, 2005, reaffirmed 2021. DOI: 10.1080/10915810500227731
European Commission. "EU CosIng database entry for Niacinamide." ec.europa.eu/growth/tools-databases/cosing
Gehring W. "Nicotinic acid/niacinamide and the skin." Journal of Cosmetic Dermatology, 2004. PubMed: 17134421
Rolfe HM. "A review of nicotinamide: treatment of skin diseases and potential side effects." Journal of Cosmetic Dermatology, 2014. PubMed: 25399625
Walocko FM, et al. "The role of nicotinamide in acne treatment." Dermatologic Therapy, 2017. PubMed: 28271622
Boo YC. "Mechanistic basis and clinical evidence for the applications of nicotinamide in dermatology." Antioxidants, 2021. DOI: 10.3390/antiox10081228
Draelos ZD, et al. "Niacinamide-containing facial moisturiser improves skin barrier and benefits subjects with rosacea." Cutis, 2005. PubMed: 15207399
Navarrete-Solís J, et al. "A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma." Dermatology Research and Practice, 2011. PubMed: 21790661
European Commission SCCS. Scientific Committee on Consumer Safety opinions archive. health.ec.europa.eu/scientific-committees

FAQ

Can pregnant women use niacinamide? Yes. ACOG and NHS categorise topical niacinamide as low-risk during pregnancy and breastfeeding. There is no documented foetal exposure signal at normal cosmetic concentrations.

What is the lowest effective concentration? 2% produces measurable benefit on barrier function. 4 to 5% is the sweet spot for efficacy with minimal adverse event risk. 10% is not systematically better than 5%.

Will niacinamide cause me to break out at first? Purging in the classical sense (accelerated turnover uncovering pre-existing microcomedones) is documented for retinoids and AHAs, not niacinamide. Any breakout during the first weeks of niacinamide use is more likely related to the vehicle ingredients than the active itself.

Is it safe long-term? Yes. The CIR assessment reviewed use across 30+ years in over 800 formulations. No cumulative safety signal has emerged.

Can I combine it with retinol? Yes. Niacinamide actually reduces retinol-associated irritation by supporting barrier function. It is a recommended pairing in modern dermatology practice.

For practical guidance on how to integrate niacinamide into a daily routine, see our retinol beginner's guide which covers combination principles. For a scored analysis of products containing niacinamide, check the SkinScore rankings filtered by this active. For our full scoring methodology including how niacinamide is weighted, read the methodology page.

For further reading

Related articles:

Resources: